- Asperuloside
-
- $55.00 / 5mg
-
2026-04-21
- CAS:14259-45-1
- Min. Order:
- Purity: 99.99%
- Supply Ability: 10g
- Asperuloside
-
- $0.00 / 20mg
-
2023-02-24
- CAS:14259-45-1
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- ASPERULOSIDE
-
- $9.80 / 1KG
-
2020-01-13
- CAS:14259-45-1
- Min. Order: 1KG
- Purity: ≥98%
- Supply Ability: 20 tons
|
| | ASPERULOSIDE Basic information |
| Product Name: | ASPERULOSIDE | | Synonyms: | ASPERULOSIDE;RUBICHLORIC ACID;[2aS-(2aalpha,4aalpha,5alpha,7balpha)]-5-(beta-D-glucopyranosyloxy)-2a,4a,5,7b-tetrahydro-1-oxo-1H-2,6-dioxacyclopent[cd]inden-4-ylmethyl acetate;1H-2,6-Dioxacyclopentcdinden-1-one, 4-(acetyloxy)methyl-5-(.beta.-D-glucopyranosyloxy)-2a,4a,5,7b-tetrahydro-, (2aS,4aS,5S,7bS)-;Asperulosid;(2aS)-2a,4aα,5,7bα-Tetrahydro-4-acetoxymethyl-5α-(β-D-glucopyranosyloxy)-1H-2,6-dioxacyclopent[cd]inden-1-one;(2As-(2aalpha,4aalpha,5alpha,7balpha))-5-(beta-D-glucopyranosyloxy)-2A,4A,5,7B-tetrahydro-1-oxo-1H-2,6-dioxacyclopent(cd)inden-4-ylmethyl acetate;1H-2,6-Dioxacyclopent(cd)inden-1-one, 4-((acetyloxy)methyl)-5-(beta-D-glucopyranosyloxy)-2A,4A,5,7B-tetrahydro-, (2as-(2aalpha,5alpha,7balpha))- | | CAS: | 14259-45-1 | | MF: | C18H22O11 | | MW: | 414.36 | | EINECS: | 238-137-5 | | Product Categories: | Miscellaneous Natural Products | | Mol File: | 14259-45-1.mol |  |
| | ASPERULOSIDE Chemical Properties |
| Melting point | 131-132° | | alpha | D25 -198.6° (c = 1.44 in water) | | Boiling point | 704.2±60.0 °C(Predicted) | | density | 1.62±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in methanol and water | | pka | 12.76±0.70(Predicted) | | form | powder | | color | White | | Major Application | metabolomics
vitamins, nutraceuticals, and natural products | | InChIKey | IBIPGYWNOBGEMH-BWDLRQFSNA-N | | SMILES | [C@]12([H])C(COC(=O)C)=C[C@]3([H])OC(=O)C(=COC1O[C@H]1[C@H](O)[C@H]([C@H](O)[C@@H](CO)O1)O)[C@]23[H] |&1:0,9,19,20,22,23,25,30,r| | | EPA Substance Registry System | 1H-2,6-Dioxacyclopent[cd]inden-1-one, 4-[(acetyloxy)methyl]-5-(?-D-glucopyranosyloxy)-2a,4a,5,7b-tetrahydro-, (2aS,4aS,5S,7bS)- (14259-45-1) |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | ASPERULOSIDE Usage And Synthesis |
| Description | Asperuloside is an iridoid glycoside that has been found in G. tunetanum and has diverse biological activities, including anti-angiogenic, anti-inflammatory, and anti-obesity properties. It reduces microvessel formation by 67% in a chick embryo chorioallantoic membrane assay when used at a concentration of 2 μg/egg. Asperuloside (20, 40, and 80 mg/L) inhibits LPS-induced increases in TNF-α, IL-1β, and IL-6 production in RAW 264.7 macrophages in a concentration-dependent manner. It reduces lung myeloperoxidase (MPO) activity and bronchoalveolar lavage fluid (BALF) levels of TNF-α, IL-1β, and IL-6 in a mouse model of LPS-induced acute lung injury when administered at doses of 20, 40, and 80 mg/kg. Dietary administration of asperuloside decreases body weight gain, white adipose tissue (WAT) weight, and the ratio of WAT weight to body weight in a high-fat diet-induced mouse model of metabolic syndrome. | | Uses | Asperuloside is an iridoid found in Paederia foetida and is an inhibitor of xanthine oxidase and is used in the treatment of various disorders including inflammatory and cardiovascular diseases. | | Definition | ChEBI: A iridoid monoterpenoid glycoside isolated from Galium verum. | | in vivo | Asperuloside (p.o., 3 mg/day, 0.3% in diet, daily, 12 weeks) reduces food intake, body weight, and adipose masses in rats consuming a high fat diet (HFD)[2].
Asperuloside (30 and 60 mg/kg, i.p., 30 days) inhibits tumor growth of U937 xenografts mice model[3].
Asperuloside (20-80 mg/kg, i.p.) relieves LPS-induced acute lung injury via inhibiting MAPK and NF-κB signaling in BALB/c mice[4].
| Animal Model: | Rats consuming a high fat diet (HFD)[2] | | Dosage: | 3 mg/day | | Administration: | p.o., 0.3% in diet, daily, 12 weeks | | Result: | Reduced body weight, energy intake, adiposity, blood glucose, and plasma insulin. |
| | IC 50 | iNOS | | References | [1] CéSAR MUOZ CAMERO . Anti-angiogenic activity of iridoids from Galium tunetanum[C]//28 3. 2018: Pages 374-377. DOI: 10.1016/j.bjp.2018.03.010
[2] JIAMING QIU . Pretreatment with the compound asperuloside decreases acute lung injury via inhibiting MAPK and NF-κB signaling in a murine model[J]. International immunopharmacology, 2016, 31: Pages 109-115. DOI: 10.1016/j.intimp.2015.12.013
[3] T. HIRATA . Anti-obesity compounds in green leaves of Eucommia ulmoides[J]. Bioorganic & Medicinal Chemistry Letters, 2011, 21 6: Pages 1786-1791. DOI: 10.1016/j.bmcl.2011.01.060 |
| | ASPERULOSIDE Preparation Products And Raw materials |
|